APUS vs BSX · $2.4M cap vs P/E 20, rev $10.65B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Boston Scientific Corp (BSX) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported BSX revenue for 2026-06-30 was $10.65B. Net income was $2.24B. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
APUS currently screens at market cap $2.4M. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Not investment advice. Open the APUS and BSX stock pages for the full models.
Not investment advice.